#Soligenix hashtag - Bluesky

@newsen.bsky.social

6 hours ago

Soligenix Highlights Year-End 2025 Financial Results and Strategic Milestones Ahead Soligenix has reported its financial results for 2025, announcing crucial milestones in its clinical trials and ongoing commitment to rare diseases.

Soligenix Highlights Year-End 2025 Financial Results and Strategic Milestones Ahead #USA #Princeton #Soligenix #HyBryte #SNGX

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

5 days ago

Soligenix Achieves Orphan Drug Status in Europe for SGX945 to Combat Behçet's Disease Soligenix has been granted orphan drug status in Europe for SGX945, aimed at treating Behçet's Disease, significantly advancing treatment options for patients.

Soligenix Achieves Orphan Drug Status in Europe for SGX945 to Combat Behçet's Disease #United_States #Princeton #Soligenix #SGX945 #Behçet's

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

1 week ago

Soligenix to Present Promising HyBryte™ Treatment Results at US Cutaneous Lymphoma Consortium Workshop 2026 Soligenix, Inc. announces the presentation of groundbreaking results for HyBryte™ treatment at the 2026 US Cutaneous Lymphoma Consortium Workshop, highlighting its potential in treating CTCL.

Soligenix to Present Promising HyBryte™ Treatment Results at US Cutaneous Lymphoma Consortium Workshop 2026 #United_States #Princeton #Soligenix #CTCL #HyBryte

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

1 week ago

Soligenix's HyBryte™ Clinical Summary: A New Hope for CTCL Treatment Soligenix, Inc. has announced an important publication summarizing the clinical trials of HyBryte™, highlighting its potential impact on CTCL treatments and patient care.

Soligenix's HyBryte™ Clinical Summary: A New Hope for CTCL Treatment #United_States #Princeton #Soligenix #CTCL #HyBryte™

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

3 weeks ago

Soligenix's SGX945 Receives UK's Promising Innovative Medicine Designation for Behçet's Disease Soligenix, Inc. has received the Promising Innovative Medicine designation from the UK authorities for their innovative treatment, SGX945, targeting Behçet's Disease.

Soligenix's SGX945 Receives UK's Promising Innovative Medicine Designation for Behçet's Disease #United_States #Princeton #Soligenix #SGX945 #Behçet's_Disease

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

1 month ago

Soligenix Gains EMA's Favor for Orphan Drug Status for SGX945 in Behçet's Disease Treatment Soligenix has successfully received a positive recommendation from the EMA for SGX945's orphan drug designation targeting Behçet's Disease, showcasing promising clinical results.

Soligenix Gains EMA's Favor for Orphan Drug Status for SGX945 in Behçet's Disease Treatment #United_States #Princeton #Soligenix #SGX945 #Behçet's_Disease

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

1 month ago

Soligenix to Showcase Major Developments at BIO Investment Summit in Miami Soligenix will present significant advancements in rare disease treatments during the BIO Investment & Growth Summit in Miami on March 2, 2026.

Soligenix to Showcase Major Developments at BIO Investment Summit in Miami #United_States #Miami_Beach #Soligenix #HyBryte #BIO_Summit

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

1 month ago

Soligenix's 2026 Outlook: Progress, Innovations, and Future Prospects in Rare Disease Treatments Soligenix, Inc. shares its 2026 roadmap detailing significant clinical milestones in rare disease therapies and expected market opportunities.

Soligenix's 2026 Outlook: Progress, Innovations, and Future Prospects in Rare Disease Treatments #USA #Princeton #Soligenix #HyBryte #SGX945

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

3 months ago

Promising Phase 2 Trial Results for SGX945 in Treating Behçet's Disease Indicate Durable Relief New findings from Soligenix reveal SGX945 shows significant potential in treating Behçet's Disease, offering hope for improved quality of life.

Promising Phase 2 Trial Results for SGX945 in Treating Behçet's Disease Indicate Durable Relief #USA #Princeton #Soligenix #SGX945 #Behçet's_Disease

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

4 months ago

Exploring the Growth of the Mycosis Fungoides Market and Innovative Treatment Developments by 2034 The mycosis fungoides market is on an upward trajectory, driven by innovative treatments and rising awareness about the disease, projected to grow significantly by 2034.

Exploring the Growth of the Mycosis Fungoides Market and Innovative Treatment Developments by 2034 #None #Soligenix #Mycosis_Fungoides #Lacutamab

1 0 0 0

Thiard News@F4F

@newsen.bsky.social

4 months ago

Soligenix Reaches Key Enrollment Milestone in HyBryte Phase 3 Trial for Lymphoma Treatment Soligenix has successfully enrolled 50 patients in its HyBryte Phase 3 clinical trial for Cutaneous T-Cell Lymphoma, paving the way for a critical interim analysis in 2026.

Soligenix Reaches Key Enrollment Milestone in HyBryte Phase 3 Trial for Lymphoma Treatment #USA #Princeton #Soligenix #CTCL #HyBryte

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

4 months ago

Soligenix Reports Q3 2025 Financial Results and Major Developments in Clinical Trials Soligenix, Inc. outlines its recent milestones and third quarter financial results for 2025, focusing on clinical trials and future strategies.

Soligenix Reports Q3 2025 Financial Results and Major Developments in Clinical Trials #United_States #Princeton #Soligenix #CTCL #HyBryte

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

5 months ago

Soligenix Announces Enhancements to Its Medical Advisory Board for HyBryte™ in Cutaneous T-Cell Lymphoma Soligenix has updated its Medical Advisory Board to enhance clinical strategies for HyBryte™, a promising therapy for cutaneous T-cell lymphoma, aiming for better patient outcomes.

Soligenix Announces Enhancements to Its Medical Advisory Board for HyBryte™ in Cutaneous T-Cell Lymphoma #United_States #Princeton #Soligenix #HyBryte #Cutaneous_T-Cell_Lymphoma

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

5 months ago

Soligenix Reaches Major Safety Milestone for HyBryte™ in Treating Cutaneous T-Cell Lymphoma Soligenix has reached a significant safety milestone in their Phase 3 trial for HyBryte™, aimed at treating cutaneous T-cell lymphoma, confirming its acceptable safety profile.

Soligenix Reaches Major Safety Milestone for HyBryte™ in Treating Cutaneous T-Cell Lymphoma #United_States #Princeton #Soligenix #CTCL #HyBryte

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

6 months ago

Soligenix Expands Medical Advisory Board for European CTCL Treatment Advancement Soligenix, Inc. has expanded its European Medical Advisory Board as they move forward with a Phase 3 clinical study for HyBryte™ in treating cutaneous T-cell lymphoma.

Soligenix Expands Medical Advisory Board for European CTCL Treatment Advancement #United_States #Princeton #Soligenix #CTCL #HyBryte

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

6 months ago

Soligenix Completes $7.5 Million Public Offering to Drive Future Growth and Development Soligenix, Inc. has successfully closed its $7.5 million public offering, aimed at funding key developments in rare disease treatments and extending its cash runway.

Soligenix Completes $7.5 Million Public Offering to Drive Future Growth and Development #USA #Princeton #Biopharmaceutical #Soligenix #SNGX

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

6 months ago

Soligenix Set to Raise $7.5 Million in Latest Public Offering for Biopharmaceutical Ventures Soligenix, a biopharmaceutical company, announced a $7.5 million public offering to support the development of therapies for rare diseases. The offering includes shares and warrants for investors.

Soligenix Set to Raise $7.5 Million in Latest Public Offering for Biopharmaceutical Ventures #USA #biopharmaceuticals #Princeton #Soligenix #Public_Offering

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

6 months ago

Soligenix Welcomes Former White House Advisor Dr. Tomas J. Philipson as Strategic Consultant Soligenix has appointed Dr. Tomas J. Philipson, the former White House economic advisor, as a strategic consultant to guide its clinical and economic strategies.

Soligenix Welcomes Former White House Advisor Dr. Tomas J. Philipson as Strategic Consultant #USA #Princeton #Soligenix #HyBryte #Tomas_Philipson

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

6 months ago

Long-Term Stability of Ebola Vaccines Shows Promise for Global Health Security Soligenix has unveiled findings on the long-term stability of their Ebola vaccines, promising advancements in vaccination logistics and safety, critical for pandemic preparedness.

Long-Term Stability of Ebola Vaccines Shows Promise for Global Health Security #United_States #Princeton #Soligenix #Ebola_Vaccine #ThermoVax

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

6 months ago

Soligenix's Participation in the H.C. Wainwright Annual Investment Conference to Showcase Innovations Soligenix, Inc. will present innovative therapies at the H.C. Wainwright 27th Annual Global Investment Conference, focusing on unmet medical needs.

Soligenix's Participation in the H.C. Wainwright Annual Investment Conference to Showcase Innovations #USA #Princeton #Biopharmaceutical #Soligenix #HyBryte

0 0 0 0

Profit Trading USA

@profittradingusa.bsky.social

7 months ago

Soligenix stock soars after FDA grants orphan drug designation Investing.com -- Soligenix (NASDAQ:SNGX) stock surged 88% after the FDA granted orphan drug designation to dusquetide, the active ingredient in SGX945, for the treatment of Behçet’s Disease. The designation follows the FDA’s review of recent Phase 2a clinical results that demonstrated biological efficacy and safety in patients with the rare autoimmune condition. Orphan drug status provides Soligenix with seven years of market exclusivity upon final FDA approval, along with potential financial benefits including government grants for clinical trials, waiver of FDA user fees for a potential New Drug Application, and certain tax credits. Behçet’s Disease affects up to 18,000 people in the U.S., 50,000 in Europe, 350,000 in Turkey, and as many as 1 million people worldwide. The condition is characterized by oral aphthous ulcers and is considered difficult to treat and incurable. "The FDA’s decision to grant orphan drug designation to the SGX945 program signifies an important step for Soligenix as we continue to advance the program and adds significantly to the existing intellectual property estate surrounding this novel technology," said Christopher J. Schaber, President and CEO of Soligenix. Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases with unmet medical needs. The orphan drug designation is designed to encourage companies to develop therapies for conditions affecting fewer than 200,000 people in the United States. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. With SNGX making headlines, savvy investors are asking: Is it truly valued fairly? In a market full of overpriced darlings, identifying true value can be challenging. InvestingPro's advanced AI algorithms have analyzed SNGX alongside thousands of other stocks to uncover hidden gems. These undervalued stocks, potentially including SNGX, could offer substantial returns as the market corrects. In 2024 alone, our AI identified several undervalued stocks that later surged by 30 or more. Is SNGX poised for similar growth? Don't miss the opportunity to find out.

Click Subscribe #Soligenix #FDA #OrphanDrug #StockMarket #Investing

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

7 months ago

FDA Approves Soligenix's Dusquetide for Behçet's Disease: A Milestone in Rare Disease Treatment Soligenix has received orphan drug designation for dusquetide, marking a significant advance in the treatment of Behçet's Disease after promising Phase 2 results.

FDA Approves Soligenix's Dusquetide for Behçet's Disease: A Milestone in Rare Disease Treatment #USA #Princeton #Soligenix #Behçet's_Disease #dusquetide

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

7 months ago